Search Results - "Roxburgh, P" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

by Drew, Y., Kaufman, B., Banerjee, S., Lortholary, A., Hong, S.H., Park, Y.H., Zimmermann, S., Roxburgh, P., Ferguson, M., Alvarez, R.H., Domchek, S., Gresty, C., Angell, H.K., Ros, V Rocher, Meyer, K., Lanasa, M., Herbolsheimer, P., de Jonge, M.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

by Cartwright, D., White, M., Crearie, C., Forte, C., Coulter, S., Brown, J., Randhawa, M., Glasspool, R., Roxburgh, P.
Published in ESMO open (01.08.2022)

Get full text

Journal Article

17 An audit comparing two different cisplatin schedules and subsequent nephrotoxicity for two different schedules used in concurrent chemoradiation: Sequential Or Concurrent Chemotherapy And Radiotherapy (SOCCAR) regime for inoperable non-small cell lung cancer

17 An audit comparing two different cisplatin schedules and subsequent nephrotoxicity for two different schedules used in concurrent chemoradiation: Sequential Or Concurrent Chemotherapy And Radiotherapy (SOCCAR) regime for inoperable non-small cell lung cancer

by Wakeham, K, Jones, R, Brisbane, I, Roxburgh, P, MacPhee, J, Hicks, J
Published in Lung cancer (Amsterdam, Netherlands) (2014)

Get full text

Journal Article

1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma

1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma

by Jones, R.L., Groisberg, R., Blay, J-Y., Colman, H., de la Fuente, M., Milhem, M., Roxburgh, P., Chao, M.M., Tian, H., Duffaud, F., Massard, C.P., Van Tine, B.A.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

63P A real-world comparison of the tolerability and toxicity of niraparib in older and younger women with high-grade serous ovarian carcinoma

63P A real-world comparison of the tolerability and toxicity of niraparib in older and younger women with high-grade serous ovarian carcinoma

by Low, S.S.P., Jaschke, M., Hollis, R., Roxburgh, P., Gourley, C.
Published in ESMO open (01.06.2024)

Get full text

Journal Article

1848P Managing hypersensitivity reactions in Ovarian malignancy – can we re-challenge successfully?

1848P Managing hypersensitivity reactions in Ovarian malignancy – can we re-challenge successfully?

by Mclaren, A., Cartwright, D., Roxburgh, P., Stanley, B., Brown, J., Lindsay, D., Glasspool, R.M.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

$11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts$

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

by Krebs, M.G., Majem Tarruella, M., Forster, M., Peguero, J.A., Clay, T., Felip, E., Iams, W., Roxburgh, P., Doger de Spéville, B., Bajaj, P., Mueller, C., Triebel, F.
Published in Annals of oncology (01.04.2022)

Get full text

Journal Article

716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers

716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers

by Middleton, G., Marshall, L., Billingham, L., Duffus, K.D., Greystoke, A., Carter, L., Forster, M.D., Cook, N., Hargrave, D., Danson, S., Roxburgh, P., Beggs, A.D., Chaturvedi, A., Chesler, L., Sarmiento-Castro, A., Dive, C., Rothwell, D., Gath, J., Halford, S., Krebs, M.G.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

by Majem, M., Forster, M.D., Krebs, M.G., Peguero, J., Clay, T.D., Felip, E., Iams, W., Roxburgh, P., de Spéville, B. Doger, Bajaj, P., Mueller, C., Triebel, F.
Published in Journal of thoracic oncology (01.04.2023)

Get full text

Journal Article

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer

by Lolkema, M.P, Harrington, K, Evans, J, Arkenau, H.T, Roxburgh, P, Morrison, R, Roulstone, V, Coffey, M, Mettinger, K, de Bono, J
Published in European journal of cancer supplements (2009)

Get full text

Journal Article

750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

by Friedman, C., De Burgh Williams, A., Lopez, J.S., Ouali, K., Middleton, M.R., Thistlethwaite, F., Hamid, O., Izar, B., Garcia, V. Moreno, Johnson, M.L., Davar, D., Martin-Liberal, J., Roxburgh, P., Moore, K.N., Olson, D., Rottey, S., Kirk, P.B., Yuan, Y., Marshall, S., Yeku, O.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

by Banerjee, S., Imbimbo, M., Roxburgh, P., Kim, J-W., Kim, M.H., Plummer, R., Stemmer, S., You, B., Ferguson, M., Penson, R.T., O'Malley, D., Meyer, K., Gao, H., Angell, H., Tablante Nunes, A., Domchek, S., Drew, Y.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

by Forster, M., Felip, E., Doger, B., Lopez Pousa, A., Carcereny, E., Bajaj, P., Church, M., Peguero, J., Roxburgh, P., Triebel, F.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

$EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC$

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

by Forster, M., Krebs, M., Majem, M., Peguero, J., Clay, T., Felip, E., Iams, W., Roxburgh, P., Doger, B., Bajaj, P., Kefas, J., Scott, J.-.A., Barba Joaquín, A., Mueller, C., Triebel, F.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular targets trial for cervical cancer

69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular targets trial for cervical cancer

by Bello Roufai, D., Sadozye, A., Glasspool, R.M., Limaye, S., Mandic, A., Popovic, M., Ottevanger, N., Roxburgh, P., Lecuru, F., Larbi Cherif, L., Kamal, M., Le Tourneau, C., Rouzier, R., Scholl, S.
Published in Annals of oncology (01.10.2020)

Get full text

Journal Article

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

by Drew, Y., Penson, R.T., O'Malley, D.M., Kim, J-W., Zimmermann, S., Roxburgh, P., Sohn, J., Stemmer, S.M., Bastian, S., Ferguson, M., You, B., Domchek, S., Gao, H., Angell, H., Meyer, K., Opincar, L., Ottesen, L., Koralek, D.O., Banerjee, S.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

by McNeish, I.A., Moreno, V., Jayson, G., Roxburgh, P., Ginesta, M P Barretina, Garcia-Donas, J., Torres, A Anton, Michael, A., Brown, R., Krige, D., Bendall, J., Di Genova, G., McElwaine-Johnn, H.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

1031POCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

1031POCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

by McNeish, I A, Moreno, V, Jayson, G, Roxburgh, P, Ginesta, M P Barretina, Garcia-Donas, J, Torres, A Anton, Michael, A, Brown, R, Krige, D, Bendall, J, Di Genova, G, McElwaine-Johnn, H
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

by Drew, Y., Kaufman, B., Banerjee, S., Lortholary, A., Hong, S.H., Park, Y.H., Zimmermann, S., Roxburgh, P., Ferguson, M., Alvarez, R.H., Domchek, S., Gresty, C., Angell, H.K., Ros, V Rocher, Meyer, K., Lanasa, M., Herbolsheimer, P., de Jonge, M.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

1031P - OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

1031P - OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

by McNeish, I.A., Moreno, V., Jayson, G., Roxburgh, P., Ginesta, M P Barretina, Garcia-Donas, J., Torres, A Anton, Michael, A., Brown, R., Krige, D., Bendall, J., Di Genova, G., McElwaine-Johnn, H.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article